Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
Date:8/8/2012

ALISO VIEJO, Calif., Aug. 8, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine months ended June 30, 2012.

Quarterly Financial Highlights

  • Gross and net NUEDEXTA® sales of $12.2 million and $10.1 million, respectively
  • Total company net revenues of $10.5 million
  • Cash, cash equivalents, and restricted investments of $84.1 million as of June 30, 2012
  • "Our fiscal third quarter results reflect another significant increase in net sales of NUEDEXTA seen in both our retail and institutional business," said Keith A. Katkin, president and CEO of Avanir. "Going forward, our commercial team will continue to drive revenue growth by increasing recognition of pseudobulbar affect and awareness of NUEDEXTA as the only FDA-approved treatment."

    Fiscal 2012 Third Quarter Results

  • Total net revenues for the quarter ended June 30, 2012 were $10.5 million, compared with $2.5 million for the comparable quarter in 2011. Total net revenues consist of NUEDEXTA revenue and royalty revenue from Abreva®.
  • Total operating expenses were $24.7 million in the third quarter of fiscal 2012, compared with $18.4 million in the comparable period in fiscal 2011.
  • Cash used in operations was $14.9 million in the third quarter of fiscal 2012.
  • Net loss for the fiscal 2012 third quarter was $15.0 million, or $0.11 per share, compared with a net loss of $16.1 million, or $0.13 per share, for the same period in fiscal 2011.
  • Nine-Month Results

  • Total net revenues for the first nine-months of fiscal 2012 totaled $27.7 million, compared with $5.7 million for the first nine-months of fiscal 2011.
  • Total operating expenses were $74.1 million in the first nine-months of fiscal 2012, compared to $48.1 million in the comparable period for fiscal 2011.
  • Cash used in operations was $45.6 million in the first nine-months of fiscal 2012.
  • Net loss for the first nine-months of fiscal 2012 was $48.0 million, or $0.36 per share, compared with a net loss of $42.6 million, or $0.36 per share for the comparable period in fiscal 2011.
  • NUEDEXTA RevenueFor the quarter ended June 30, 2012, the company reported NUEDEXTA gross and net revenue of $12.2 million and $10.1 million.

    Cash, Cash Equivalents & Marketable SecuritiesAs of June 30, 2012 Avanir had cash, cash equivalents and investments in securities totaling $84.1 million, including cash and cash equivalents of $81.7 million and restricted investments in securities of $2.4 million.

    Business HighlightsRecent highlights for the company include:

  • Achieved record total NUEDEXTA prescriptions of 26,428 for the quarter ended June 30, 2012
  • The United States Patent and Trademark Office (USPTO) issued the patent number 8,227,484, entitled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders." The new patent was subsequently listed in the FDA Orange Book and will expire on July 17, 2023.
  • On June 11, 2012, the company announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).
  • On June 1, 2012, the company announced preliminary results from the PRISM patient registry indicating significant prevalence estimates of PBA across multiple neurologic populations including dementia, stroke, ALS, MS and TBI.
  • Note to Investors: As previously announced, Avanir will hold a conference call to discuss fiscal 2012 third quarter financial results today, August 8, 2012, beginning at 1:30 p.m. Pacific Time. You can listen to this call by dialing 1 (888) 396-2298 for domestic callers or +1 (617) 847- 8708 for international callers, and entering passcode 62935757. Those interested in listening to the conference call live via the Internet may do so by visiting http://ir.avanir.com.

    About NUEDEXTANUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

    NUEDEXTA Important Safety InformationNUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state.

    Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias.

    NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) 20/10 mg capsules can interact with other medications causing significant changes in blood levels of those medications and/or NUEDEXTA which may lead to serious side effects. Adjust dose or use alternate treatment of the other medication when clinically indicated.

    NUEDEXTA is contraindicated in patients concomitantly taking: QT-prolonging drugs metabolized by CYP2D6 (e.g., thioridazine and pimozide); monoamine oxidase inhibitors (MAOIs) within the preceding or following 14 days; other drugs containing quinidine, quinine, or mefloquine and in patients with a known hypersensitivity to these drugs or any of NUEDEXTA's components. Discontinue use of NUEDEXTA if hepatitis, thrombocytopenia, serotonin syndrome or a hypersensitivity reaction occurs.

    NUEDEXTA is contraindicated in patients with certain risk factors for arrhythmia: Prolonged QT interval; congenital long QT syndrome, history suggestive of torsades de pointes; heart failure; complete atrioventricular (AV) block or risk of AV block without an implanted pacemaker.

    NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk for QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation should be conducted at baseline and 3-4 hours after the first dose. Risk factors include left ventricular hypertrophy or dystrophy or concomitant use of drugs that prolong QT interval or certain CYP3A4 inhibitors.

    The most common adverse reactions are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma-glutamyltransferase, and flatulence. NUEDEXTA may cause dizziness. Precautions to reduce the risk of falls should be taken, particularly for patients with motor impairment affecting gait or a history of falls.

    These are not all the risks from use of NUEDEXTA. Please refer to the accompanying full Prescribing Information or visit www.NUEDEXTA.com.

    About Avanir Pharmaceuticals, Inc.Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

    Avanir® and NUEDEXTA® are registered trademarks owned by Avanir Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

    ©2012 Avanir Pharmaceuticals, Inc. All Rights Reserved.

    Forward Looking StatementsExcept for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Avanir's operating performance and financial position, the market demand for and acceptance of Avanir's products domestically and internationally, research, development and commercialization of new products domestically and internationally, obtaining additional indications for commercially marketed products domestically and internationally, obtaining and maintaining regulatory approvals domestically and internationally, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

    Avanir Investor & Media Contact
    Ian Clements, PhD
    ir@avanir.com
    +1 (949) 389-6700

     AVANIR PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETSJune 30,September 30,20122011(unaudited)(audited)ASSETSCurrent assets:Cash and cash equivalents

    $
    81,726,922$
    79,542,564Trade receivables, net

    4,968,3152,011,165Inventories, net

    371,475252,244Prepaid expenses and other current assets

    1,443,2491,965,748Current portion of restricted investments in marketable securities 

    1,054,463618,314Total current assets

    89,564,42484,390,035Restricted investments in marketable securities, net of current portion

    1,302,1361,634,625Property and equipment, net

    1,939,2441,695,329Non-current inventories, net

    937,577792,933Other assets

    1,117,9731,136,072TOTAL ASSETS$
    94,861,354$
    89,648,994LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable, accrued expenses and other liabilities

    $
    4,258,098$
    ,449,427Deferred product revenues, net

    -1,652,788Current portion of deferred royalty revenues

    2,021,1892,087,226Total current liabilities

    16,279,28714,189,441Accrued expenses and other liabilities, net of current portion

    74,85068,487Note Payable

    28,722,254Deferred royalty revenues, net of current portion

    2,693,3874,051,402Total liabilities

    47,769,77818,309,330Total stockholders' equity

    47,091,57671,339,664TOTAL LIABILITIES AND STOCKHOLDERS'  EQUITY$
    94,861,354$
    89,648,994 

     AVANIR PHARMACEUTICALS, INC.CONDENSED STATEMENTS OF OPERATIONSThree Months Ended June 30,Nine Months Ended June 30,2012201120122011REVENUES AND COSTS FROM PRODUCT SALESGross product sales

    $
    2,205,811$
    2,187,124$
    29,676,740$
    2,692,090Less: discounts and allowances

    2,155,238254,8894,995,531297,841Net product sales

    10,050,5731,932,23524,681,2092,394,249Cost of product sales

    563,527119,2081,407,675233,535Product gross margin

    9,487,0461,813,02723,273,5342,160,714OTHER REVENUESRevenues from royalties

    487,423547,9003,062,0583,340,876Total other revenues

    487,423547,9003,062,0583,340,876Total gross margin9,974,4692,360,92726,335,5925,501,590OPERATING EXPENSESResearch and development

    6,831,2063,258,95016,970,8769,622,129Selling, general and administrative

    17,855,26915,150,05357,091,29238,522,264Total operating expenses

    24,686,47518,409,00374,062,16848,144,393Loss from operations(14,712,006)(16,048,076)(47,726,576)(42,642,803)OTHER INCOME (EXPENSE)Interest income

    7,89010,84830,06328,031Interest expense

    (326,098)(326,098)Other, net

    -(28,332)4,081(28,295)Loss before provision for income taxes(15,030,214)(16,065,560)(48,018,530)(42,643,067)Provision for income taxes

    ----Net loss and comprehensive loss$
    (15,030,214)$
    (16,065,560)$
    (48,018,530)$
    (42,643,067)Basic and diluted net loss per share$
    (0.11)$
    (0.13)$
    (0.36)$
    (0.36)Basic and diluted weighted average number of common shares outstanding 

    135,825,005123,354,986132,391,195117,747,185 

     


    '/>"/>
    SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
    4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
    5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
    8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
    9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
    10. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
    (Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
    (Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
    (Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
    Breaking Biology Technology:
    (Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
    (Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
    (Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
    Breaking Biology News(10 mins):